Phase 1 study on the safety and pharmacokinetics of trametinib, gilteritinib or everolimus with dexamethasone in patients with relapsed or refractory acute B-lymphoblastic leukemia.
MULTICENTER CLINICAL TRIAL
We warmly invite you to participate in an open, multicenter clinical trial aimed at evaluating the safety and pharmacokinetics, and determining the maximum tolerated and therapeutic dose of three kinase inhibitors: trametinib, gilteritinib or everolimus in combination with dexamethasone in adult oncology patients.
In case of technical problems, please contact:
BioStat Sp. z o.o.
ul. Kowalczyka 17, 44-206 Rybnik
tel: 666 069 834
email: [email protected]
Login to the eCRF system